Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Michael Doumas and Christodoulos Papadopoulos.
Michael Doumas
Connection Strength
1.436
Christodoulos Papadopoulos
  1. Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors? Kardiol Pol. 2021; 79(9):1048-1049.
    View in: PubMed
    Score: 0.239
  2. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. Diabetes Obes Metab. 2021 Jul; 23(7):1696-1700.
    View in: PubMed
    Score: 0.233
  3. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Pol Arch Intern Med. 2020 10 29; 130(10):922.
    View in: PubMed
    Score: 0.228
  4. Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes Ther. 2020 Dec; 11(12):3003-3005.
    View in: PubMed
    Score: 0.227
  5. Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. Acta Diabetol. 2021 01; 58(1):125-126.
    View in: PubMed
    Score: 0.225
  6. Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. SN Compr Clin Med. 2020; 2(9):1419-1429.
    View in: PubMed
    Score: 0.224
  7. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov; 40(11):4671-4674.
    View in: PubMed
    Score: 0.060
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.